PF-670462 |
رقم الكتالوجGC10556 |
An inhibitor of the CK1 isoforms CK1ε and CK1δ
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 950912-80-8
Sample solution is provided at 25 µL, 10mM.
PF-670462 is a potent and selective inhibitor of CK1ε and CK1δ with IC50 value of 80 nM and 13 nM, respectively [1].
CK1ε and CK1δ belong to the casein kinase 1 family which is serine/threonine-selective enzyme and plays an important role in regulating circadian rhythm [1].
In COS-7 cells cotransfected with GFP-tagged PER3 and the human CK1ε enzyme, PF-670462 inhibited PER3 nuclear translocation in a concentration-dependent way [2]. In primary lung fibroblast cells obtained from WT mice, PF-670462 significantly lengthened the circadian period in a dose-dependent way. And with a dose of 1 μM, the period in WT fibroblast cells extended to 33 h [3].
In WT, Ck1ε−/− and Ck1εtau mice, PF-670462 (10 mg/kg/d) significantly lengthened the period of activity rhythms in all three genotypes (WT: 0.44 h, Ck1εtau: 0.39 h, Ck1ε−/−: 0.42 h). In WT mice, the activity onset occurred 10.4 h after 24 d of treatment. Also, PF-670462 caused identical period lengthening in WT and Ck1ε−/− mice, which suggested that the effect of CK1δ on the circadian period [3].
References:
[1]. Walton KM, Fisher K, Rubitski D, et al. Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther, 2009, 330(2): 430-439.
[2]. Badura L, Swanson T, Adamowicz W, et al. An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions. J Pharmacol Exp Ther, 2007, 322(2): 730-738.
[3]. Meng QJ, Maywood ES, Bechtold DA, et al. Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. Proc Natl Acad Sci U S A, 2010, 107(34): 15240-15245.
Kinase experiment [1]: | |
Kinase assays |
The CK1ε and CK1δ kinase assays were performed in a 20-μL volume in buffer containing 50 mM Tris, pH 7.5, 10 mM MgCl2, 1 mM DTT, 10 μM ATP and 42 μM peptide substrate (PLSRTLpSVASLPGL). The final enzyme concentrations were 2.5 nM for CK1ε and 2 nM for CK1δ. Assays were run in a panel format in the presence 1 μL of CK1 inhibitor or 5% DMSO. The reactions were incubated for 2 hrs at room temperature, followed by detection with 20 μL of the Kinase-Glo Plus Assay reagent. Luminescence was measured by using Enhanced Lum detection on an Envision plate reader. |
Cell experiment [1]: | |
Cell lines |
Rat1 cells |
Preparation method |
The solubility of this compound in DMSO is > 20.5 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
Reacting condition |
0 ~ 50 μM |
Applications |
In Rat1 cells, PF-670462 significantly lengthened the circadian period. At the concentration as low as 1 μM, PF-670462 started to dramatically increase the circadian period in a dose-dependent manner. PF-670462 began to increase the period of the clock at approximately 3- to 10-fold over the whole-cell CK1δ IC50 and approximately 3-fold lower for CK1ε. |
Animal experiment [1]: | |
Animal models |
C57BL/6J mice |
Dosage form |
32 mg/kg; s.c.; a single dose |
Applications |
After a single subcutaneous dose of 32 mg/kg PF-670462, the brain-to-plasma concentration ratio of PF-670462 was constant throughout the 24-hr time course, with an average value of 1.3. The free brain Cmax of PF-670462 was 3-fold above its CK1δ whole-cell IC50, along with a 0.7-fold CK1ε whole-cell IC50, which indicated that PF-670462 inhibited most of the CK1δ and CK1ε activity. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Walton KM, Fisher K, Rubitski D, et al. Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther, 2009, 330(2): 430-439. |
Cas No. | 950912-80-8 | SDF | |
Chemical Name | 4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine;dihydrochloride | ||
Canonical SMILES | C1CCC(CC1)N2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F.Cl.Cl | ||
Formula | C19H22Cl2FN5 | M.Wt | 410.32 |
الذوبان | ≥ 20.5 mg/mL in DMSO, ≥ 20.8 mg/mL in EtOH with ultrasonic and warming, ≥ 94 mg/mL in Water with ultrasonic and warming | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.4371 mL | 12.1856 mL | 24.3712 mL |
5 mM | 0.4874 mL | 2.4371 mL | 4.8742 mL |
10 mM | 0.2437 mL | 1.2186 mL | 2.4371 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *